Danielle Guerrero

Press Release: Leica Biosystems Announces Partnership with Indica Labs to Deliver Integrated Digital Pathology Workflow Solutions for Mutual Customers

Vista, CA – Sep 4, 2022, Leica Biosystems, a cancer diagnostics company and a global leader in workflow solutions, and Indica Labs, the industry-leading provider of computational and image management software in digital pathology, today announced a partnership focused on delivering compatible digital pathology workflow solutions.

Press Release: Leica Biosystems Announces Partnership with Indica Labs to Deliver Integrated Digital Pathology Workflow Solutions for Mutual Customers Read More »

Press Release: Indica Labs Announces Collaboration with The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics (iCAIRD) for the Development of an AI-based Algorithm for the Automated Reporting of Lymph Node Status in Colon Cancer

Albuquerque, NM, and Glasgow, Scotland, – 30 August, 2022 – Indica Labs, an industry leader in quantitative digital pathology and image management solutions, and The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics (iCAIRD), announced today an agreement to collaborate on the development of an AI-based digital pathology solution for the detection of cancer within lymph nodes from colorectal surgery cases.

Press Release: Indica Labs Announces Collaboration with The Industrial Centre for Artificial Intelligence Research in Digital Diagnostics (iCAIRD) for the Development of an AI-based Algorithm for the Automated Reporting of Lymph Node Status in Colon Cancer Read More »

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer

Predictive biomarkers to determine which non small cell lung cancer (NSCLC) patients will respond to immunotherapy are currently lacking. In this Nature Cancer publication, the

Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer Read More »

Scroll to Top